XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated
The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.

Evolent Health ServicesClinical SolutionsIntersegment
Eliminations		Subtotal
Corporate (1)
Consolidated
Revenue
For the Three Months Ended June 30, 2021
Transformation services$2,564 $— $— $2,564 $— $2,564 
Platform and operations services72,759 147,194 (460)219,493 — 219,493 
Total revenue$75,323 $147,194 $(460)$222,057 $— $222,057 
For the Three Months Ended June 30, 2020
Transformation services$755 $— $— $755 $— $755 
Platform and operations services86,432 130,780 (668)216,544 — 216,544 
Total revenue$87,187 $130,780 $(668)$217,299 $— $217,299 
Evolent Health ServicesClinical SolutionsSubtotal
Corporate (1)
Segments Total
For the Three Months Ended June 30, 2021
Adjusted EBITDA$6,531 $13,597 $20,128 $(6,782)$13,346 
For the Three Months Ended June 30, 2020
Adjusted EBITDA$6,948 $12,200 $19,148 $(8,629)$10,519 

Evolent Health ServicesClinical SolutionsIntersegment
Eliminations		Subtotal
Corporate (1)
Consolidated
Revenue
For the Six Months Ended June 30, 2021
Transformation services$2,909 $— $— $2,909 $— $2,909 
Platform and operations services157,700 277,417 (898)434,219 — 434,219 
Total revenue$160,609 $277,417 $(898)$437,128 $— $437,128 
For the Six Months Ended June 30, 2020
Transformation services$5,993 $— $— $5,993 $— $5,993 
Platform and operations services178,222 255,652 (1,336)432,538 — 432,538 
Total revenue$184,215 $255,652 $(1,336)$438,531 $— $438,531 
Evolent Health ServicesClinical SolutionsSubtotal
Corporate (1)
Segments Total
For the Six Months Ended June 30, 2021
Adjusted EBITDA$12,473 $29,573 $42,046 $(13,793)$28,253 
For the Six Months Ended June 30, 2020
Adjusted EBITDA$11,716 $19,243 $30,959 $(16,564)$14,395 
————————
(1)Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.
Reconciliation of Adjusted EBITDA to net loss
The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2021202020212020
Net loss attributable to common shareholders of Evolent Health, Inc.$(9,107)$(203,521)$(18,914)$(282,273)
Less:
Interest income68 705 191 1,475 
Interest expense(6,274)(6,290)(12,611)(12,571)
(Provision) benefit for income taxes(91)3,904 (702)3,634 
Depreciation and amortization expenses(14,916)(15,618)(30,103)(31,596)
Equity method investment impairment— — — (47,133)
Gain on transfer of membership— — 22,969 — 
Loss on repayment of debt, net— — (19,158)— 
Goodwill impairment— (215,100)— (215,100)
Gain from equity method investees4,879 25,143 12,662 24,731 
Loss on disposal of assets— — — (6,447)
Change in fair value of contingent consideration and indemnification asset— (756)594 3,062 
Other expense, net(18)354 (32)284 
Repositioning costs(663)— (6,043)— 
Stock-based compensation expense(3,653)(3,703)(7,359)(7,211)
Severance costs— (30)(52)(6,133)
Amortization of contract cost assets(196)(767)(323)(1,207)
Strategy and shareholder advisory expenses(1,513)— (6,513)— 
Acquisition costs(76)(374)(2,070)(683)
Gain (loss) from discontinued operations (1)
— (1,508)1,383 (1,773)
Adjusted EBITDA$13,346 $10,519 $28,253 $14,395 
————————
(1)Includes $1.9 million gain on disposal of discontinued operations for the six months ended June 30, 2021.